PMID: 6108353Dec 1, 1980Paper

Catecholamine-sensitive guanylate cyclase from human caudate nucleus

Journal of Neurochemistry
W H FreyS E Nicol

Abstract

Partial purification of soluble guanylate cyclase on DEAE-Sephacel yields two separate peaks of guanylate cyclase activity. After 10-fold purification of the soluble enzyme, guanylate cyclase is markedly inhibited by micromolar concentrations of dopamine (I50 = 0.2 microM). Dopamine inhibition is observed whether the reaction is conducted with Mn2+ or with Mg2+, under atmosphere or N2(g), and using enzyme from either peak from the DEAE-Sephacel column. Other catecholamines also inhibit partially purified guanylate cyclase with an order of potency at 1 microM of: dopamine = L-DOPA > norepinephrine = isoproterenol = adrenochrome > epinephrine. The structural requirements for inhibition are two free hydroxyl groups on the phenyl ring and an ethylamine side chain. Dopamine also inhibits the Triton X-100-solubilized microsomal guanylate cyclase after partial purification on DEAE-Sephacel. Neither chlorpromazine, propranolol, nor phentolamine at 20 microM effectively block the dopamine inhibition of partially purified soluble guanylate cyclase. Micromolar concentrations of the reducing agents dithiothreitol and glutathione also inhibit partially purified guanylate cyclase, but unlike these agents, catecholamines can inhibit whether a...Continue Reading

References

Sep 15, 1975·Life Sciences·H Kimura, F Murad
May 1, 1976·Life Sciences·D R OlsonB M Breckenridge
Apr 1, 1976·Neuropharmacology·S J StradaW J Thompson
Jan 1, 1977·Annual Review of Biochemistry·N D Goldberg, M K Haddox
Oct 1, 1977·Proceedings of the National Academy of Sciences of the United States of America·C K Mittal, F Murad
Jan 1, 1976·Analytical Biochemistry·H L CaillaM A Delaage
Jan 11, 1979·Nature·J W Kebabian, D B Calne
Aug 1, 1975·Journal of Neurochemistry·Y C Clement-CormierP Greengard
Jan 1, 1976·Schizophrenia Bulletin·H Y Meltzer, S M Stahl
Apr 1, 1974·Proceedings of the National Academy of Sciences of the United States of America·Y C Clement-CormierP Greengard
Dec 30, 1971·Annals of the New York Academy of Sciences·G A Robison, E W Sutherland
Jul 16, 1973·European Journal of Biochemistry·D von Hungen, S Roberts
Aug 1, 1974·Journal of Neurochemistry·P KleihuesK A Hossmann
Aug 1, 1972·Proceedings of the National Academy of Sciences of the United States of America·J W KebabianP Greengard
Apr 1, 1964·Biochemistry·W W CLELAND

❮ Previous
Next ❯

Citations

May 1, 1988·The Histochemical Journal·G Poeggel, H Luppa
Jan 1, 1983·Neuroscience and Biobehavioral Reviews·J N Joyce
Jul 1, 1989·Toxicology Letters·A BindoliL Galzigna
Oct 1, 1992·Free Radical Biology & Medicine·A BindoliD J Deeble
Oct 1, 1981·The Journal of Cell Biology·M A Ariano, A I Matus
Jan 7, 1998·The Journal of Cell Biology·Y LiD Schubert
Apr 14, 1981·Biochimica Et Biophysica Acta·W H FreyS E Nicol

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here